IBDEI2MA ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1446,0)
 ;;=ESTABLISHED PATIENT^1^114
 ;;^UTILITY(U,$J,358.4,1447,0)
 ;;=CONSULTATIONS^3^114
 ;;^UTILITY(U,$J,358.4,1448,0)
 ;;=PREGNANCY COMPLICATIONS^21^115
 ;;^UTILITY(U,$J,358.4,1449,0)
 ;;=PREGNANCY-HYPERTENSION^24^115
 ;;^UTILITY(U,$J,358.4,1450,0)
 ;;=PREGNANCY-VOMITING^27^115
 ;;^UTILITY(U,$J,358.4,1451,0)
 ;;=LATE PREGNANCY^15^115
 ;;^UTILITY(U,$J,358.4,1452,0)
 ;;=PREGNANCY-OTH COMPLICATIONS^25^115
 ;;^UTILITY(U,$J,358.4,1453,0)
 ;;=PREGNANCY CONDITIONS^22^115
 ;;^UTILITY(U,$J,358.4,1454,0)
 ;;=MULTIPLE GESTATIONS^18^115
 ;;^UTILITY(U,$J,358.4,1455,0)
 ;;=PREGNANCY-FETAL ABNORMALITY^23^115
 ;;^UTILITY(U,$J,358.4,1456,0)
 ;;=AMNIO/MEMBRANE PROBLEMS^3^115
 ;;^UTILITY(U,$J,358.4,1457,0)
 ;;=MAJOR PUERPERAL INFECTIONS^16^115
 ;;^UTILITY(U,$J,358.4,1458,0)
 ;;=VENOUS COMPLICATIONS^32^115
 ;;^UTILITY(U,$J,358.4,1459,0)
 ;;=PREGNANCY-PYREXIA^26^115
 ;;^UTILITY(U,$J,358.4,1460,0)
 ;;=PUERPERIUM COMPLICATIONS^29^115
 ;;^UTILITY(U,$J,358.4,1461,0)
 ;;=INFECTION-BREAST/NIPPLE IN PREGNANCY^12^115
 ;;^UTILITY(U,$J,358.4,1462,0)
 ;;=PREGNANCY-Z CODES^28^115
 ;;^UTILITY(U,$J,358.4,1463,0)
 ;;=GENITOURINARY & RENAL^11^115
 ;;^UTILITY(U,$J,358.4,1464,0)
 ;;=DIGESTIVE^9^115
 ;;^UTILITY(U,$J,358.4,1465,0)
 ;;=VAGINA^31^115
 ;;^UTILITY(U,$J,358.4,1466,0)
 ;;=VULVA^33^115
 ;;^UTILITY(U,$J,358.4,1467,0)
 ;;=UTERUS^30^115
 ;;^UTILITY(U,$J,358.4,1468,0)
 ;;=PREGNANCY^20^115
 ;;^UTILITY(U,$J,358.4,1469,0)
 ;;=PAIN SYNDROME^19^115
 ;;^UTILITY(U,$J,358.4,1470,0)
 ;;=MENOPAUSE^17^115
 ;;^UTILITY(U,$J,358.4,1471,0)
 ;;=INFERTILITY^14^115
 ;;^UTILITY(U,$J,358.4,1472,0)
 ;;=ENDOCRINE^10^115
 ;;^UTILITY(U,$J,358.4,1473,0)
 ;;=INFECTION-D/C & PARASITIC DISEASES^13^115
 ;;^UTILITY(U,$J,358.4,1474,0)
 ;;=DERMATOLOGY^8^115
 ;;^UTILITY(U,$J,358.4,1475,0)
 ;;=CONTRACEPTION-HRT^7^115
 ;;^UTILITY(U,$J,358.4,1476,0)
 ;;=CERVICAL^6^115
 ;;^UTILITY(U,$J,358.4,1477,0)
 ;;=BREAST^5^115
 ;;^UTILITY(U,$J,358.4,1478,0)
 ;;=BLEEDING (NON-PREGNANT)^4^115
 ;;^UTILITY(U,$J,358.4,1479,0)
 ;;=ADNEXA^2^115
 ;;^UTILITY(U,$J,358.4,1480,0)
 ;;=GENERAL-GLOBAL^1^115
 ;;^UTILITY(U,$J,358.4,1481,0)
 ;;=SPECIAL SERVICES^9^116
 ;;^UTILITY(U,$J,358.4,1482,0)
 ;;=CHEMO NURSE PROCEDURES^2^116
 ;;^UTILITY(U,$J,358.4,1483,0)
 ;;=INFUSION DRUGS^6^116
 ;;^UTILITY(U,$J,358.4,1484,0)
 ;;=BLOOD PRODUCTS^1^116
 ;;^UTILITY(U,$J,358.4,1485,0)
 ;;=DIAGNOSTIC PROCEDURES^3^116
 ;;^UTILITY(U,$J,358.4,1486,0)
 ;;=OTHER DRUGS^7^116
 ;;^UTILITY(U,$J,358.4,1487,0)
 ;;=IMMUNIZATION ADMINISTRATION^4^116
 ;;^UTILITY(U,$J,358.4,1488,0)
 ;;=IMMUNIZATIONS^5^116
 ;;^UTILITY(U,$J,358.4,1489,0)
 ;;=PROLONGED SERVICES^8^116
 ;;^UTILITY(U,$J,358.4,1490,0)
 ;;=NEW PATIENT^2^117
 ;;^UTILITY(U,$J,358.4,1491,0)
 ;;=ESTABLISHED PATIENT^1^117
 ;;^UTILITY(U,$J,358.4,1492,0)
 ;;=CONSULTATIONS^3^117
 ;;^UTILITY(U,$J,358.4,1493,0)
 ;;=ANEMIA^1^118
 ;;^UTILITY(U,$J,358.4,1494,0)
 ;;=ARTIFICIAL OPENING STATUS^2^118
 ;;^UTILITY(U,$J,358.4,1495,0)
 ;;=BREASTS and GYN NEOPLASMS^3^118
 ;;^UTILITY(U,$J,358.4,1496,0)
 ;;=COAGULATION DISORDERS^4^118
 ;;^UTILITY(U,$J,358.4,1497,0)
 ;;=COUNSELING AND SCREENING^5^118
 ;;^UTILITY(U,$J,358.4,1498,0)
 ;;=GENITOURINARY NEOPLASMS^6^118
 ;;^UTILITY(U,$J,358.4,1499,0)
 ;;=GI CANCER^7^118
 ;;^UTILITY(U,$J,358.4,1500,0)
 ;;=HEAD NECK AND LUNGS NEOPLASMS^8^118
 ;;^UTILITY(U,$J,358.4,1501,0)
 ;;=HEMOGLOBINOPATHIES^9^118
 ;;^UTILITY(U,$J,358.4,1502,0)
 ;;=LYMPHOID NEOPLASMS^10^118
 ;;^UTILITY(U,$J,358.4,1503,0)
 ;;=METASTATIC SITES^11^118
 ;;^UTILITY(U,$J,358.4,1504,0)
 ;;=MALIGNANT NEOPLASMS OF OTHER SITES^12^118
 ;;^UTILITY(U,$J,358.4,1505,0)
 ;;=MYELOID NEOPLASMS AND DISORDERS^13^118
